Innovation and Competitiveness
The global competitive ability of Haemopharm is an aspect of crucial importance to its customers, who are increasingly sensitive regarding the launch of new partnerships with operators in the sector, who not only can offer an excellent product, but are also able to guarantee an extensive presence worldwide. Haemopharm has developed over the years many strategic commercial agreements, thanks to which it is now present and active in many countries across Europe, North and South America, Australia and the Far East. Particularly in Serbia, it operates with Quatalia Science d.o.o., a pharmaceutical company which completes the Group's offer, thanks to numerous Marketing Authorizations, especially for oncological treatment, antibiotics and medical devices.
With headquarters in Belgrade, it has been established to consolidate local business and to facilitate the emerging markets penetration.